Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia

Lawrence Einhorn, W. H. Bond

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prednisone plus vincristine plus daunomycin induced complete remission in nine adults with acute lymphocytic leukemia. The median duration of complete remission will be between 14 and 18 months, with three patients remaining in hematological remission at 1 ()<sup>+</sup>, 11<sup>+</sup>, and 18<sup>+</sup> months. The median survival will be between 19 and 23 months, with all patients surviving at least one year. This remission induction regimen produced rapid complete remission in adult acute lymphocytic leukemia (ALL) w'ith minimal toxicity, and could be administered predominantly on an outpatient basis.

Original languageEnglish
Pages (from-to)25-28
Number of pages4
JournalOncology
Volume34
Issue number1
DOIs
StatePublished - 1977

Fingerprint

Remission Induction
Daunorubicin
Vincristine
Prednisone
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Outpatients
Survival

Keywords

  • Daunomycin-Chemotherapy-Adult acute lymphocytic leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia. / Einhorn, Lawrence; Bond, W. H.

In: Oncology, Vol. 34, No. 1, 1977, p. 25-28.

Research output: Contribution to journalArticle

@article{f18de248ecb64b7eaa77580842104554,
title = "Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia",
abstract = "Prednisone plus vincristine plus daunomycin induced complete remission in nine adults with acute lymphocytic leukemia. The median duration of complete remission will be between 14 and 18 months, with three patients remaining in hematological remission at 1 ()+, 11+, and 18+ months. The median survival will be between 19 and 23 months, with all patients surviving at least one year. This remission induction regimen produced rapid complete remission in adult acute lymphocytic leukemia (ALL) w'ith minimal toxicity, and could be administered predominantly on an outpatient basis.",
keywords = "Daunomycin-Chemotherapy-Adult acute lymphocytic leukemia",
author = "Lawrence Einhorn and Bond, {W. H.}",
year = "1977",
doi = "10.1159/000225176",
language = "English",
volume = "34",
pages = "25--28",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia

AU - Einhorn, Lawrence

AU - Bond, W. H.

PY - 1977

Y1 - 1977

N2 - Prednisone plus vincristine plus daunomycin induced complete remission in nine adults with acute lymphocytic leukemia. The median duration of complete remission will be between 14 and 18 months, with three patients remaining in hematological remission at 1 ()+, 11+, and 18+ months. The median survival will be between 19 and 23 months, with all patients surviving at least one year. This remission induction regimen produced rapid complete remission in adult acute lymphocytic leukemia (ALL) w'ith minimal toxicity, and could be administered predominantly on an outpatient basis.

AB - Prednisone plus vincristine plus daunomycin induced complete remission in nine adults with acute lymphocytic leukemia. The median duration of complete remission will be between 14 and 18 months, with three patients remaining in hematological remission at 1 ()+, 11+, and 18+ months. The median survival will be between 19 and 23 months, with all patients surviving at least one year. This remission induction regimen produced rapid complete remission in adult acute lymphocytic leukemia (ALL) w'ith minimal toxicity, and could be administered predominantly on an outpatient basis.

KW - Daunomycin-Chemotherapy-Adult acute lymphocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=0017685250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017685250&partnerID=8YFLogxK

U2 - 10.1159/000225176

DO - 10.1159/000225176

M3 - Article

C2 - 266674

AN - SCOPUS:0017685250

VL - 34

SP - 25

EP - 28

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -